Noninvasive diagnosis of Helicobacter pylori among patients with dyspepsia

Abstract

Introduction: Helicobacter pylori (H. pylori) infection is a common disease with disparity in geography, age, race and socioeconomic status. Present study aims to assess the accuracy of noninvasive diagnostic tests.
 Methods: This is a hospital based cross sectional, observational study of 100 dyspeptic patients during November 2017- June 2018. Profile of dyspeptic patients were recorded in a proforma and accuracy of serology and stool antigen test for H. pylori was compared with histology detection in gastric biopsies.
 Results: Mean age of patients was 39.5±13.7 years with almost equal gender distribution. Prevalence of H. pylori was 56% with dyspeptic symptoms in gastric biopsies. Significant association of the infection was seen in patients with a longer duration of dyspepsia, pangastritis on endoscopy and chronic gastritis on histologic examination. Stool antigen test had good sensitivity (71%) and specificity (82%) for H. pylori detection compared with standard histological diagnosis.
 Conclusion: Overall prevalence of H. pylori was 56% and was more common in patients of age > 44 years with dyspepsia. Stool antigen has a good diagnostic accuracy and can be used in resource limited settings. However, we recommend a community based study in larger population.

Diagnostic Accuracy of Serologic (IGG) in Diagnosis of Helicobacter Pylori among Patients of Dyspepsia by Taking Stool Antigen (HPSA) as Gold Standard

“…4 Invasive procedures (histological examination, culture, and quick urease test) and non-invasive approaches (serology, urea breath test, and stool antigen) can all be used to identify H. pylori infection, with various degrees of sensitivity and specificity. 6 In a developing countries like Pakistan, the accessibility, expense, invasiveness, nature, and easiness of achievement of these tests all play a role. 6 A accurate identification and delivery of H. pylori eradication therapy will decrease the occurrence of gastroduodenal disorders, such as gastric carcinoma, linked to H. pylori infection, as well as the number of new infections in the future.…”

“…6 In a developing countries like Pakistan, the accessibility, expense, invasiveness, nature, and easiness of achievement of these tests all play a role. 6 A accurate identification and delivery of H. pylori eradication therapy will decrease the occurrence of gastroduodenal disorders, such as gastric carcinoma, linked to H. pylori infection, as well as the number of new infections in the future. 7 H. pylori antibodies, including immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, are tested serologically.…”